NUVB today
$4.05-$0.24 (-5.48%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourSymmetric Triangle
15 minStrong Bearish
5 minSymmetric Triangle
Daily trend turns up above $5.06
Key levels
Resistance$4.36
Resistance$4.07
Support$3.31
Support$2.99
About Nuvation Bio
Nuvation Bio is an oncology-focused biopharmaceutical company that develops treatments for cancer. Its main product, taletrectinib, is approved for a type of lung cancer driven by ROS1 alterations and is sold in the United States, Japan, and China through partners. The company also develops safusidenib for IDH1-mutant brain tumors and has a pipeline of drug-drug conjugates. It operates globally.
Based on the company's 10-K filed Mar 2, 2026.
NYSE · Healthcare
Nuvation Bio Inc. (NUVB)
What Is the Price Target for NUVB?
SEPT Low Target
$11.00
SEPT Mid Target
$13.00
SEPT High Target
$21.00
Analyst Consensus
$13.00
Is NUVB a Buy or Sell Right Now?
Thesis
- •Revenue growing 699.0% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NUVB.
Start Free Trial →Is NUVB Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$477.36
7
Moat Score
NONE
3/9
Piotroski Score
-2.7
Altman Z-Score
What Is Smart Money Doing with NUVB?
Insider Signal
SELLING
1 buys / 5 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Markel Stacy | officer | Buy | 90,380 | $169K | Jun 23, 2026 |
| Markel Stacy | officer | Buy | 34,620 | $60K | Jun 23, 2026 |
| Markel Stacy | officer | Sale | 125,000 | $753K | Jun 23, 2026 |
| Wentworth Kerry | officer | Buy | 63,000 | $185K | Jun 23, 2026 |
| Wentworth Kerry | officer | Sale | 63,000 | $379K | Jun 23, 2026 |
| Mashal Robert | director | Buy | 25,000 | $118K | Jun 9, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NUVB Growth Story
Revenue YoY
699.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
71.56%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for NUVB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NUVB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:20:51 | $4.06 | 1,200 | $$5K | BUY |
| 15:20:37 | $4.06 | 5,000 | $$20K | BUY |
| 15:17:42 | $4.07 | 1,000 | $$4K | BUY |
| 15:17:23 | $4.07 | 2,000 | $$8K | BUY |
| 15:17:03 | $4.07 | 1,500 | $$6K | SELL |
5 dark pool trades shown · $$43K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Nuvation Bio Inc. (NUVB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NUVB — frequently asked questions
What is NUVB stock price today?
Nuvation Bio Inc. (NUVB) is at $4.05, down 5.48% (-$0.24) at the Nov 12, 2026 close.
Why is NUVB stock moving today?
Latest NUVB news — Nov 9, 2026: J.P. Morgan keeps Buy rating on Nuvation Bio
What is the NUVB price target?
The average analyst price target for NUVB is $13.00, ranging from $11 to $21, based on 5 analysts. Latest: Citigroup initiates on Sep 30, 2026.
What do analysts rate NUVB?
Analyst ratings for NUVB: 0 Buy, 13 Hold, 0 Sell — consensus Hold.
Did NUVB beat earnings?
NUVB last reported on Aug 6, 2026: EPS -$0.15 vs -$0.14 expected — a miss of 5.9%.
Does NUVB pay a dividend?
NUVB does not currently pay a dividend.
How much debt does NUVB have?
Nuvation Bio Inc. reported $243M of debt and $259M of cash (Jun 30, 2026).
What are NUVB support and resistance levels?
Support: $3.31, $2.99, $2.57. Resistance: $4.07, $4.36, $4.85.
What are insiders doing with NUVB?
Insider activity: SELLING, 1 buys and 5 sells in the last 90 days.
What is the latest news on NUVB?
Nov 9, 2026: J.P. Morgan keeps Buy rating on Nuvation Bio